Abstract illustration of blue, purple, and pink particles on a navy blue background.

Cardiac rhythm technologies

TruAF™ detection algorithm

The TruAF™ detection algorithm allows healthcare professionals to detect atrial fibrillation (AF) without an atrial lead.

Indications, Safety, and WarningsThe Visia AF™ and Visia AF MRI™ SureScan™ ICD systems automatically detect and record the occurrence of atrial fibrillation (AF) for diagnostic purposes. The AF Detection feature analyzes variability in the ventricular rate to determine whether the patient is currently experiencing atrial fibrillation. Evidence of atrial fibrillation is based on ventricular rate variability assessed via a Lorenz plot.
The Visia AF MRI™ SureScan™ ICD models are MR Conditional and, as such are designed to allow patients to be safely scanned by an MRI machine when used according to the specified MRI conditions for use. When programmed to “on,” the MRI SureScan™ feature allows the patient to be safely scanned while the device continues to provide appropriate pacing.Indications for useThe Visia™ AF and Visia AF MRI™ SureScan™ ICD systems are indicated to provide ventricular antitachycardia pacing and ventricular defibrillation for automated treatment of life-threatening ventricular arrhythmias.A complete Visia AF MRI™ SureScan™ defibrillation system is required for use in the MR environment. A complete Visia AF MRI™ SureScan™ defibrillation system includes a Visia AF MRI™ VR SureScan™ ICD device with a SureScan™ defibrillation lead. When a single coil SureScan™ defibrillation lead is used, a Medtronic DF-1 pin plug must be secured in the SVC port to make a complete SureScan™ DF-1 defibrillation system. To verify that components are part of a SureScan™ system, visit mrisurescan.com. Any other combination may result in a hazard to the patient during an MRI scan.ContraindicationsThe Visia™ AF and Visia AF MRI™ ICDs are contraindicated for patients experiencing tachyarrhythmias with transient or reversible causes including, but not limited to, the following: acute myocardial infarction, drug intoxication, drowning, electric shock, electrolyte imbalance, hypoxia, or sepsis; patients who have a unipolar pacemaker implanted, patients with incessant VT or VF, and patients whose primary disorder is atrial tachyarrhythmia.Warnings and precautionsChanges in patient’s disease and/or medications may alter the efficacy of the device’s programmed parameters. Patients should avoid sources of magnetic and electromagnetic radiation to avoid possible underdetection, inappropriate sensing and/or therapy delivery, tissue damage, induction of an arrhythmia, device electrical reset, or device damage. Do not place transthoracic defibrillation paddles directly over the device.For Visia AF MRI™ System only:
Patients and their implanted systems must be screened to meet the following requirements for MRI: no implanted lead extenders, lead adaptors, or abandoned leads; no broken leads or leads with intermittent electrical contact as confirmed by lead impedance history; a SureScan™ defibrillation system implanted in the left or right pectoral region; pacing capture thresholds of ≤ 2.0 V at a pulse width of 0.4 ms; no diaphragmatic stimulation at a pacing output of 5.0 V and at a pulse width of 1.0 ms in patients whose device will be programmed to an asynchronous pacing mode when MRI SureScan™ is programmed to “on.”Patients may be scanned using a horizontal field, cylindrical bore, clinical 1.5T or 3T MRI system for hydrogen proton imaging, maximum spatial gradient ≤ 20 T/m, and maximum gradient slew rate performance per axis ≤ 200 T/m/s. 1.5T scanners must be operated in Normal Operating Mode (whole body averaged specific absorption rate (SAR) ≤ 2.0 W/kg, head SAR ≤ 3.2 W/kg). 3T scanners must be operated in First Level Controlled Operating Mode or Normal Operating Mode. B_1+RMSmust be ≤ 2.8 μT when the isocenter (center of the bore) is inferior to the C7 vertebra. Scans can be performed without B_1+RMS restriction when the isocenter is at or superior to the C7 vertebra.Continuous patient monitoring is required while MRI SureScan™ is programmed to “on.” While MRI SureScan™ is programmed to “on,” arrhythmia detection and therapies are suspended, leaving the patient at risk of death from untreated spontaneous tachyarrhythmia. In addition, if the device is programmed to an asynchronous pacing mode, arrhythmia risk may be increased.Potential complicationsPotential complications include, but are not limited to, rejection phenomena, erosion through the skin, muscle or nerve stimulation, oversensing, failure to detect and/or terminate tachyarrhythmia episodes, acceleration of ventricular tachycardia, and surgical complications such as hematoma, infection, inflammation, and thrombosis. Other potential complications related to the lead may include lead dislodgement, lead conductor fracture, insulation failure, threshold elevation, or exit block.Potential MRI complications for the Visia AF MRI™ SureScan™ system include, but are not limited to, lead electrode heating and tissue damage resulting in loss of sensing or capture or both, or induced currents on leads resulting in continuous capture, VT/VF, and/or hemodynamic collapse; spontaneous tachyarrhythmia occurring during the scan that is not detected and treated because tachyarrhythmia detection is suspended while MRI SureScan™ is programmed to “on;” potential for VT/VF induction when the patient is programmed to an asynchronous pacing mode during MRI SureScan™; device heating resulting in tissue damage in the implant pocket or patient discomfort or both; or damage to the functionality or mechanical integrity of the device resulting in the inability of the device to communicate with the programmer.See the device manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential complications/adverse events for all Visia AF devices and the MRI SureScan™ technical manual before performing an MRI scan on patients with a Visia AF MRI™ system. For further information, please call Medtronic at 1-800-328-2518 and/or consult mrisurescan.com.Caution: Federal law (United States) restricts this device to sale by or on the order of a physician.MAJ_90552

Overview

Traditionally, single chamber implantable cardioverter defibrillators (ICDs) have been unable to determine whether a patient is experiencing AF episodes due to the lack of an atrial lead — until now.

With the TruAF™ detection algorithm, you can detect AF without an atrial lead.

How it works

Atrial fibrillation can conduct into the ventricle resulting in a variable heart rate, which can lead to variability in the timing of the R waves. The TruAF™ detection algorithm monitors R-R variability and looks for patterns, then determines if the variability and pattern are sufficient to meet the classification of AF.

This provides you the opportunity to determine if your patient has AF, quantify the time in AF, and determine if the ventricular rate is controlled. This information — combined with other patient factors — allows you to help manage your patients who have AF.

Clinical evidence

Multiple independent, real-world analyses demonstrate that atrial fibrillation is commonly found with Visia™ AF ICD patients.^1,2 Continuous monitoring in single chamber ICD patients may allow for early AF identification and intervention.

Detection algorithm summary

1	Does the patient have AF? Check AF episodes on interval plot and EGM		➧	Clinical decision
2	If yes, how much? Check AF burden information on Quick Look™ II and Cardiac Compass™ trends
3	If yes, is it rate controlled? Check vs. rate during AF on Cardiac Compass™ trends
4	What are the patient factors? Congestive heart failure Hypertension Diabetes mellitus Stroke/TIA/thromboembolism Vascular disease (prior MI/PAD/aortic plaque) Age Gender

Incidence of AF in single chamber ICD population

	Boriani, et al.¹	Brown, et al.²
Time period	6 months	6 months
Minimum AF detected	≥ 6 minutes	≥ 6 minutes
Patient history	Unknown AF history before implant	No prior AF history before implant
Data form	CareLink™ device database	Medtronic surveillance registry
Type of data	Real-world observational analysis	Real-world observational analysis
N=	4,920 Visia AF™ ICD patients	159 Visia AF™ ICD patients

Related links

Related products

Cobalt™ MRI SureScan™ ICD

Cobalt™ ICDs are used to treat sudden cardiac arrest and abnormal heart rhythms.

Boriani G. Understanding the incidence of AF in single-chamber ICD patients: a real-world analysis. Presented at Europace 2017.
Brown ML. New AF occurrence in single-chamber ICD patients: insights from a real-world investigation. Presented at HRS 2018.

You are leaving the Medtronic United Kingdom site

You just clicked a link to go to another website. If you continue, you will leave this site and go to a site run by someone else.

Medtronic does not review or control the content on the other website, and we are not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.

It is possible that some of the products on the other site are not approved in the United Kingdom.

First Name

Last Name

Title

STATE / PROVINCE

EMAIL

PHONE

Hospital Or Practice

Job Role

Specialty

About the latest products, technologies and services:

Yes No

About educational and clinical information (E.G. Medtronic Academy):

Yes No

Would you like to receive the Medtronic customer experience survey

Yes No

Your information will be processed and protected in accordance with our privacy statement

Selecting “no” to marketing emails above will not affect your other email selections, and a Medtronic representative will still reach out via email, if selected. Your personal data will used to manage your relationship with Medtronic, and, if you consent, to provide you with relevant email updates based on your user preferences. You can opt-out of receiving such emails at any time by clicking the unsubscribe link in the relevant email. Medtronic may use pixels and other technologies in emails to gather statistics around email opening and clicks, to help us improve our communications and to provide you with relevant content.

For more information, see the {link}.

You can always change your preferences or update your personal details by visiting the Preference center. {link}

First Name

Last Name

Title

STATE / PROVINCE

EMAIL

PHONE

Hospital Or Practice

Job Role

Specialty

About the latest products, technologies and services:

Yes No

About educational and clinical information (E.G. Medtronic Academy):

Yes No

Would you like to receive the Medtronic customer experience survey

Yes No

Your information will be processed and protected in accordance with our privacy statement

Selecting “no” to marketing emails above will not affect your other email selections, and a Medtronic representative will still reach out via email, if selected. Your personal data will used to manage your relationship with Medtronic, and, if you consent, to provide you with relevant email updates based on your user preferences. You can opt-out of receiving such emails at any time by clicking the unsubscribe link in the relevant email. Medtronic may use pixels and other technologies in emails to gather statistics around email opening and clicks, to help us improve our communications and to provide you with relevant content.

For more information, see the {link}.

You can always change your preferences or update your personal details by visiting the Preference center. {link}

First Name

Last Name

EMAIL

Hospital Or Organization

Job Role

Specialty

Confirm country/region

Before we get started, what best describes you?

OR

Confirm country/region

First Name

Last Name

EMAIL

Hospital Or Organization

Country

HOSPITAL POSTAL CODE

Job Role

Specialty

First Name

Last Name

EMAIL

PHONE

Hospital Or Organization

COUNTRY

HOSPITAL POSTAL CODE

Job Role

Specialty